CytomX's Varseta-M Receives FDA Fast-Track Designation to Treat Colorectal Cancer

08:54 AM EDT, 08/27/2026 (MT Newswires) -- CytomX Therapeutics (CTMX) has received U.S. Food and Drug Administration Fast Track Designation for Varseta-M, its drug candidate treating relapsed/refractory metastatic colorectal cancer, the company said on Thursday. FDA Fast Track Designation accelerates the review of therapies for serious, untreated medical conditions. The designation is typically granted if a therapy shows potential to improve patient survival, enhance day-to-day functioning, or prevent the condition from worsening if untreated. Shares of the biopharmaceutical company were up 5% pre-bell.